DXT by RESPINOR

Novel, non-invasive ultrasound device for accurate and continuous diaphragm monitoring
Enables early detection of diaphragm dysfunction in critical care settings
Successfully validated in clinical studies on mechanically ventilated patients
Backed by substantial funding from H2020 and The Research Council of Norway
CE-marked and EN ISO 13485:2016 certified, ensuring regulatory compliance and quality
Ready for global market adoption with ongoing efforts towards US authorization
Targets a market potential of over 350 million patients across US and EU
Developed to become the technology of choice for assessing work of breathing

What is DXT?

DXT, or Diaphragm Excursion Technology, is a groundbreaking non-invasive medical device developed by RESPINOR that utilizes ultrasound for operator-independent, continuous monitoring of the diaphragm, the main breathing muscle, in critically ill patients.

This technology aids in the early detection of diaphragm dysfunction and enhances clinical decision-making in critical care settings.

Key Benefits and Clinical Applications of DXT

Clinically proven output:
‍DXT measures diaphragm excursion (DE) and respiratory rate (RR) in real-time including trends. DXT has a well-established cut-off value to detect patients at increased risk of reintubation during the weaning process from MV.
Medical Need:
‍By identifying patients at increased risk of extubation failure during the weaning process from mechanical ventilation, RESPINOR DXT has the potential to improve decision making and reduce the number of emergency re-intubations, and potential morbidity associated with mechanical ventilation, as well as ICU and hospital length of stay.
Purpose:
‍DXT aims to optimize extubation timing, reduce re-intubation rates, improve patient outcomes, and thereby lower healthcare costs.
Technology:
DXT uses sensors with optimized design for patient comfort, continuous monitoring, and computer-aided sensor placement.
Non-Invasive:
DXT offers a non-invasive solution for monitoring diaphragm function.
Good safety profile:
A total of 389 patients been monitored with DXT through the clinical development, and no serious adverse device effects have been reported
Product:
‍RESPINOR DXT is a medical technology designed to provide an objective measure of diaphragm function.

Recent updates from RESPINOR

August 4, 2025

RESPINOR Secures CE Mark for RESPINOR DXT Under EU MDR – Enabling European Market Launch

November 22, 2024

The FDA has designated RESPINOR DXT as a Breakthrough Device

July 16, 2024

Operator independent continuous ultrasound monitoring of diaphragm excursion predicts successful weaning from mechanical ventilation: a prospective observational study, Demoule et al. Critical Care (2024) 28:245.

RESPINOR has successfully completed the clinical evidence program for the first indication, weaning from mechanical ventilation (MV), and is now preparing for regulatory submission both in Europe and the US.

July 21, 2023

RESPINOR announces new Chair of the Board

On July 21, 2023, RESPINOR AS, a clinical-stage medical device company, appointed Anders Wold as Chair of the Board, effective immediately. Wold brings four decades of healthcare and ultrasound industry leadership to the role, having previously served as President and CEO of GE Healthcare Clinical Care Solutions. The current Chair, Aage Bryn, will become a Board member, while the rest of the Board will maintain their positions. Wold's expertise in the ultrasound business and international MedTech connections will support RESPINOR in commercializing and launching their innovative DXT product. Wold expressed enthusiasm for joining RESPINOR and looks forward to addressing unmet clinical needs in respiratory care.

December 9, 2022

First patient included in the multicenter, multinational DE-RISK WF II study in Europe

The first patient has been successfully included in the DE-RISK WF II study at the coordinating center, Hôpitaux Universitaires Pitié Salpêtrière, in Paris.

The non-invasive ultrasound-based medical device